CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism

Summary

Landmark paper identifying CD38 — an NAD+-consuming ecto-enzyme — as the principal driver of age-related NAD+ decline in mammalian tissues. Using CD38-knockout mice, Camacho-Pereira and colleagues showed that old CD38-/- animals retained youthful NAD+ levels across liver, muscle, and adipose tissue, whereas wild-type tissues exhibited the canonical 50-70% drop by 24 months of age. CD38 protein expression increased with age in multiple tissues, and pharmacological CD38 inhibition (78c and related compounds) was sufficient to rescue tissue NAD+ in aged wild-type mice. The NAD+ restoration in CD38-/- animals reversed mitochondrial dysfunction in a SIRT3-dependent fashion, normalizing oxygen consumption, membrane potential, and metabolic flexibility. This established CD38 as the dominant NADase in aging mammals, reframed the NAD+ decline as an enzymatic consumption problem rather than a biosynthetic deficit, and opened CD38 inhibition as a therapeutic axis distinct from precursor supplementation.

Frequently asked questions

What did Camacho-Pereira et al. (2016) find about NAD+?

CD38 upregulation with age is the primary driver of tissue NAD+ decline; CD38 loss preserves NAD+ and mitochondrial function via SIRT3. Source: Camacho-Pereira J, Tarragó MG, Chini CCS, et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metabolism, 2016.

What kind of study is Camacho-Pereira 2016?

It is a mechanism study on NAD+ published in Cell Metabolism in 2016. Landmark paper identifying CD38 — an NAD+-consuming ecto-enzyme — as the principal driver of age-related NAD+ decline in mammalian tissues. Using CD38-knockout mice, Camacho-Pereira and colleagues showed that old CD38-/- animals retained youthful NAD+ levels across liver, muscle, and adipose tissue, whereas wild-type tissues exhibited the canonical 50-70% drop by 24 months of age. CD38 protein expression increased with age in multiple tissues, and pharmacological CD38 inhibition (78c and related compounds) was sufficient to rescue tissue NAD+ in aged wild-type mice. The NAD+ restoration in CD38-/- animals reversed mitochondrial dysfunction in a SIRT3-dependent fashion, normalizing oxygen consumption, membrane potential, and metabolic flexibility. This established CD38 as the dominant NADase in aging mammals, reframed the NAD+ decline as an enzymatic consumption problem rather than a biosynthetic deficit, and opened CD38 inhibition as a therapeutic axis distinct from precursor supplementation.

Where can I read the full Camacho-Pereira 2016 paper?

The primary source is available on PubMed (PMID 27304511) and via DOI 10.1016/j.cmet.2016.05.006.

Access the full paper

Related research